Β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol

American Journal of Hypertension

Volumn 25, Issue 8, 2012, Pages 920-926

  Vardeny, Orly ^a   Nicholas, Gabriel ^b   Andrei, Alina ^b   Buhr, Kevin A ^b   Hermanson, Matt P ^a   Moran, John J ^a   Detry, Michelle A ^b   Stein, James H ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

adrenergic receptor gene polymorphism; blocker; blood pressure; hypertension; triglycerides

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; METOPROLOL SUCCINATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARBAZOLES; FEMALE; HUMANS; INSULIN; MALE; METOPROLOL; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; TRIGLYCERIDES;

EID: 84864277171     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.54     Document Type: Article

References (35)

1. Taylor MR, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail 2004; 10:281-288.
2. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84:46-50. (Pubitemid 17013575)
3. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters S P, Weiss ST, Bleecker ER. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006; 174:1101-1109. (Pubitemid 44772080)
4. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, Glorioso N. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004; 4:154-160. (Pubitemid 38786553)
5. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee T Y, Pepine CJ, Johnson JA; INVEST Investigators. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84:715-721.
6. Vardeny O, Detry MA, Moran JJ, Johnson MR, Sweitzer NK. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. J Cardiovasc Pharmacol 2008; 52:500-506.
7. Rosmond R, Ukkola O, Chagnon M, Bouchard C, Björntorp P. Polymorphisms of the beta2-adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in men. J Intern Med 2000; 248:239-244.
8. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236. (Pubitemid 39473160)
9. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme W, Scherhaug A. Effects of metoprolol and carvedilol on preexisting and new on-set diabetes in patients with chronic heart failure {inverted exclamation}V data from the Carvedilol or metoprolol European Trial (COMET). Heart 2007; 8:968-973. (Pubitemid 47122050)
10. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14:489-494. (Pubitemid 26161099)
11. Jacob S, Balletshofer B, Henriksen EJ, Volk A, Mehnert B, Löblein K, Häring HU, Rett K. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 1999; 8:261-268. (Pubitemid 30220288)
12. Gudbjörnsdóttir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Mårin P, Lönnroth P. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. Eur J Clin Invest 1997; 27:29-35. (Pubitemid 27065170)
13. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84:205-213. (Pubitemid 19170111)
14. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43:533-549. (Pubitemid 30322070)
15. Insel PA. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 1996; 334:580-585.
16. Lithell H, Pollare T, Berne C, Saltin B. The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Press 1992; 1:20-26.
17. Fonarow GC, Deedwania P, Fonseca V, Nesto RW, Watson K, Tarka E, Lukas MA, Madan A, Shabbout M. Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. J Am Soc Hypertens 2009; 3:210-220.
18. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007; 115:450-458. (Pubitemid 46184196)
19. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9419. (Pubitemid 24272896)
20. Lima JJ, Matsushima N, Kissoon N, Wang J, Sylvester JE, Jusko WJ. Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Clin Pharmacol Ther 2004; 76:27-37. (Pubitemid 38844731)
21. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65:682-689. (Pubitemid 10179730)
22. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P, Hamsten A. The Q/E27 polymorphism in the beta2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins. J Intern Med 2000; 247:651-656. (Pubitemid 30430341)
23. González Sánchez JL, Proenza AM, Martínez Larrad MT, Ramis JM, Fernández Pérez C, Palou A, Serrano Ríos M. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol (Oxf) 2003; 59:476-481. (Pubitemid 37188178)
24. Carlsson M, Orho-Melander M, Hedenbro J, Groop LC. Common variants in the beta2-(Gln27Glu) and beta3-(Trp64Arg)-adrenoceptor genes are associated with elevated serum NEFA concentrations and type II diabetes. Diabetologia 2001; 44:629-636. (Pubitemid 32411280)
25. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat Metab Disord 2000; 24:382-387. (Pubitemid 30137732)
26. Petrone A, Zavarella S, Iacobellis G, Zampetti S, Vania A, Di Pietro S, Galgani A, Leonetti F, Di Mario U, Buzzetti R. Association of beta2 adrenergic receptor polymorphisms and related haplotypes with triglyceride and LDL-cholesterol levels. Eur J Hum Genet 2006; 14:94-100. (Pubitemid 43019089)
27. Echwald SM, Sørensen TI, Tybjaerg-Hansen A, Andersen T, Pedersen O. Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-onset obesity in Danish men. Diabetes 1998; 47:1657-1658. (Pubitemid 28445358)
28. Kortner B, Wolf A, Wendt D, Beisiegel U, Evans D. Lack of association between a human beta-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. Int J Obes Relat Metab Disord 1999; 23:1099-1100. (Pubitemid 29476214)
29. Kawamura T, Egusa G, Fujikawa R, Okubo M. Gln27Glu variant of the beta2-adrenergic receptor gene is not associated with obesity and diabetes in Japanese-Americans. Metab Clin Exp 2001; 50:443-446. (Pubitemid 32321953)
30. Isaza CA, Henao J, Sánchez JC, Porras GL, Cardona J, Bedoya G. Beta-2-adrenergic receptor polymorphisms and changes in lipids induced by metoprolol. Pharmacology 2007; 80:279-285. (Pubitemid 47557262)
31. Iaccarino G, Trimarco V, Lanni F, Cipolletta E, Izzo R, Arcucci O, De Luca N, Di Renzo G. beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. Pharmacogenomics J 2005; 5:292-297. (Pubitemid 41508640)
32. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT Jr, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL; GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 2007; 120:610-615. (Pubitemid 46977319)
33. Sharp R P, Sirajuddin R, Sharief IM. Impact of carvedilol on the serum lipid profile. Ann Pharmacother 2008; 42:564-571. (Pubitemid 351521971)
34. Hagström-Toft E, Enoksson S, Moberg E, Bolinder J, Arner P. beta-Adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. Am J Physiol 1998; 275:E909-E916.
35. Holm C, Belfrage P, Fredrikson G. Immunological evidence for the presence of hormone-sensitive lipase in rat tissues other than adipose tissue. Biochem Biophys Res Commun 1987; 148:99-105.